Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.26355/eurrev_202008_22659 http://scihub22266oqcxt.onion/10.26355/eurrev_202008_22659 32894567!ä!32894567 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Rev+Med+Pharmacol+Sci 2020 ; 24 (16): 8592-8605 Nephropedia Template TP {{tp|p=32894567|t=2020. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review |pdf=|usr=}}{{32894567}} gab.com Text Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review JO: Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32894567 #FOAvip OBJECTIVE: Lopinavir/ritonavir has been used for the treatment of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronavirus infections. It has been suggested that, based on this experience, this drug should also be studied in SARS-CoV2 infection. MATERIALS AND METHODS: We performed a systematic review of the literature regarding the use of lopinavir/ritonavir for the treatment of these three infections. We systematically searched the PubMed database from inception to April 30th, 2020, to identify in-vitro and animal studies and any reports of human use of lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19. We also searched the Clinicatrial.gov to identify ongoing trials. RESULTS: Five in-vitro studies evaluated the effect of lopinavir/ritonavir in SARS. Three additional in-vitro studies reported the EC50 of the antiviral activity of lopinavir/ritonavir in MERS. We identified no in vitro studies evaluating the effect of lopinavir/ritonavir on the novel coronavirus. Two retrospective matched-cohort studies reported the use of lopinavir/ritonavir in combination with ribavirin for SARS patients. Three case reports and one retrospective study described the use of lopinavir/ritonavir in MERS. Twenty-two papers describe the use of lopinavir/ritonavir in adult patients with COVID-19. CONCLUSIONS: The existing literature does not suffice for assessing whether Lopinavir/ritonavir has any benefit in SARS, MERS or COVID-19. Twit Text FOAVip Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review ????Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32894567 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32894567 #FOAvip English Wikipedia <ref>{{Cite pmid|32894567}}</ref> Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review #MMPMID32894567 Vargas M; Servillo G; Einav S Eur Rev Med Pharmacol Sci 2020[Aug]; 24 (16): 8592-8605 PMID32894567show ga OBJECTIVE: Lopinavir/ritonavir has been used for the treatment of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronavirus infections. It has been suggested that, based on this experience, this drug should also be studied in SARS-CoV2 infection. MATERIALS AND METHODS: We performed a systematic review of the literature regarding the use of lopinavir/ritonavir for the treatment of these three infections. We systematically searched the PubMed database from inception to April 30th, 2020, to identify in-vitro and animal studies and any reports of human use of lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19. We also searched the Clinicatrial.gov to identify ongoing trials. RESULTS: Five in-vitro studies evaluated the effect of lopinavir/ritonavir in SARS. Three additional in-vitro studies reported the EC50 of the antiviral activity of lopinavir/ritonavir in MERS. We identified no in vitro studies evaluating the effect of lopinavir/ritonavir on the novel coronavirus. Two retrospective matched-cohort studies reported the use of lopinavir/ritonavir in combination with ribavirin for SARS patients. Three case reports and one retrospective study described the use of lopinavir/ritonavir in MERS. Twenty-two papers describe the use of lopinavir/ritonavir in adult patients with COVID-19. CONCLUSIONS: The existing literature does not suffice for assessing whether Lopinavir/ritonavir has any benefit in SARS, MERS or COVID-19. |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/isolation & purification[MESH] |COVID-19[MESH] |Clinical Studies as Topic[MESH] |Coronavirus Infections/*drug therapy/pathology/virology[MESH] |Databases, Factual[MESH] |Humans[MESH] |Lopinavir/*therapeutic use[MESH] |Middle East Respiratory Syndrome Coronavirus/*drug effects/metabolism[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/pathology/virology[MESH] |Ritonavir/*therapeutic use[MESH] |SARS-CoV-2[MESH]Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a sy(epmc).pdf DeepDyve Pubget Overpricing